NCT02497157View on ClinicalTrials.gov

Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Oxaliplatin (L-OHP)

DRUG

Irinotecan hydrochloride hydrate (CPT-11)

DRUG

Continuous intravenous infusion of fluorouracil (CIV 5-FU)

DRUG

Levofolinate calcium (l-LV)

DRUG

Bevacizumab (Bmab)

Trial Locations (7)

790-8524

Matsuyama Red Cross Hospital, Matsuyama

761-0793

Kagawa University Hospital, Kita-gun, Miki-cho

701-0192

Kawasaki Medical School Hospital, Kurashiki

700-8511

Okayama Saiseikai General Hospital, Okayama

700-8558

Okayama University Hospital, Okayama

702-8055

Okayama Rosai Hospital, Okayama

773-8502

Tokushima Red Cross Hospital, Komatsushimachō

All Listed Sponsors
collaborator

Hiroshima Prefectural Hospital

UNKNOWN

collaborator

National Hospital Organization Shikoku Cancer Center

UNKNOWN

lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

NCT02497157 - Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter